Chronic Hepatitis C

Choosing amantadine for hepatitis C therapy could be impractical

Published in Hepatitis Weekly, March 4th, 2002

by Sonia Nichols, senior medical writer - Physicians in Switzerland don't believe a combination of amantadine and interferon is any better than standard interferon/ribavirin combination therapy for improving viral infection in patients with chronic hepatitis C.

Because the combination is expensive and does not significantly reduce viral load over other current hepatitis C virus (HCV) treatment regimens, the researchers would not recommend it for supplanting combination therapy that includes ribavirin, based on the results of their large-scale double-blind, placebo-controlled study.

The efficacy of amantadine/combination therapy for treating hepatitis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry